Sobrerol in the treatment of secretory otitis media in childhood.
The therapeutic activity and tolerability of sobrerol, a muco-active agent, were evaluated in 30 children (aged 5-10 years) with secretory otitis media. The drug was administered once daily by inhalation for 10 days consecutively at a dose of 40 mg/3 ml. Clinical assessments showed a significant improvement in the objective measures together with good tolerability. Moreover, sobrerol was shown to improve impedance values; this is an important aspect of the modifications induced by this drug in diseases involving the ear.
Bellussi
L
L
Medical School, Ear, Nose and Throat Department, University of Aquila, Italy.
Bernocchi
D
D
Ciferri
G
G
Manini
G
G
Passali
D
D
D002648:Child; D002675:Child, Preschool; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006320:Hearing Tests; D006801:Humans; D008297:Male; D015394:Molecular Structure; D010033:Otitis Media / Q000188:drug therapy*; D010035:Otitis Media, Suppurative / Q000188:drug therapy* / Q000503:physiopathology; D013729:Terpenes / Q000627:therapeutic use*
D005100:Expectorants; D013729:Terpenes; C003316:sobrerol